Sebastian Blecha1, Florian Zeman2, Magdalena Rohr3, Frank Dodoo-Schittko3, Susanne Brandstetter3, Christian Karagiannidis4, Christian Apfelbacher3, Thomas Bein5. 1. Department of Anaesthesiology, University Medical Centre Regensburg, Regensburg, Germany. 2. Centre of Clinical Studies, University Medical Centre Regensburg, Regensburg, Germany. 3. Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany. 4. Department of Pneumology and Critical Care Medicine, Cologne-Merheim Hospital, ARDS and ECMO Centre, Kliniken der Stadt Köln gGmbH, Witten/Herdecke University Hospital, Cologne, Germany. 5. Faculty of Medicine, University of Regensburg, Regensburg, Germany.
Abstract
BACKGROUND: The acute respiratory distress syndrome (ARDS) is a life-threatening condition with the risk of developing hypoxia and thus requires for invasive mechanical ventilation a long-term analgosedation. Yet, prolonged analgosedation may be a reason for declining health-related quality of life (HRQoL) and the development of psychiatric disorders. METHODS: We used data from the prospective observational nation‑wide ARDS study across Germany (DACAPO) to investigate the influence of sedation and analgesia on HRQoL and the risk of psychiatric symptoms in ARDS survivors 3, 6 and 12 months after their discharge from the intensive care unit (ICU). HRQoL was measured with the Physical and Mental Component Scale of the Short‑Form 12 Questionnaire (PCS‑12, MCS‑12). The prevalence of psychiatric symptoms (depression and post‑traumatic stress disorder [PTSD]) was assessed using the Patient Health Questionnaire‑9 and the Post‑Traumatic Stress Syndrome‑14. The associations of analgosedation with HRQoL and psychiatric symptoms were investigated by means of multivariable linear regression models. RESULTS: The data of 134 ARDS survivors (median age [IQR]: 55 [44-64], 67% men) did not show any significant association between analgosedation and physical or mental HRQoL up to 1 year after ICU discharge. Multivariable linear regression analysis (B [95%‑CI]) yielded a significant association between symptoms of psychiatric disorders and increased cumulative doses of ketamine up to 6 months after ICU discharge (after 3 months: depression: 0.15 [0.05, 0.25]; after 6 months: depression: 0.13 [0.03, 0.24] and PTSD: 0.42 [0.04, 0.80)]). CONCLUSIONS: Up to 1 year after ICU discharge, analgosedation did not influence HRQoL of ARDS survivors. Prolonged administration of ketamine during ICU treatment, however, was positively associated with the risk of psychiatric symptoms. The administration of ketamine to ICU patients with ARDS should be with caution. TRIAL REGISTRATION: Clinicaltrials.gov: NCT02637011 (Registered 15 December 2015, retrospectively registered).
BACKGROUND: The acute respiratory distress syndrome (ARDS) is a life-threatening condition with the risk of developing hypoxia and thus requires for invasive mechanical ventilation a long-term analgosedation. Yet, prolonged analgosedation may be a reason for declining health-related quality of life (HRQoL) and the development of psychiatric disorders. METHODS: We used data from the prospective observational nation‑wide ARDS study across Germany (DACAPO) to investigate the influence of sedation and analgesia on HRQoL and the risk of psychiatric symptoms in ARDS survivors 3, 6 and 12 months after their discharge from the intensive care unit (ICU). HRQoL was measured with the Physical and Mental Component Scale of the Short‑Form 12 Questionnaire (PCS‑12, MCS‑12). The prevalence of psychiatric symptoms (depression and post‑traumatic stress disorder [PTSD]) was assessed using the Patient Health Questionnaire‑9 and the Post‑Traumatic Stress Syndrome‑14. The associations of analgosedation with HRQoL and psychiatric symptoms were investigated by means of multivariable linear regression models. RESULTS: The data of 134 ARDS survivors (median age [IQR]: 55 [44-64], 67% men) did not show any significant association between analgosedation and physical or mental HRQoL up to 1 year after ICU discharge. Multivariable linear regression analysis (B [95%‑CI]) yielded a significant association between symptoms of psychiatric disorders and increased cumulative doses of ketamine up to 6 months after ICU discharge (after 3 months: depression: 0.15 [0.05, 0.25]; after 6 months: depression: 0.13 [0.03, 0.24] and PTSD: 0.42 [0.04, 0.80)]). CONCLUSIONS: Up to 1 year after ICU discharge, analgosedation did not influence HRQoL of ARDS survivors. Prolonged administration of ketamine during ICU treatment, however, was positively associated with the risk of psychiatric symptoms. The administration of ketamine to ICU patients with ARDS should be with caution. TRIAL REGISTRATION: Clinicaltrials.gov: NCT02637011 (Registered 15 December 2015, retrospectively registered).
Authors: O Joseph Bienvenu; Lisa Aronson Friedman; Elizabeth Colantuoni; Victor D Dinglas; Kristin A Sepulveda; Pedro Mendez-Tellez; Carl Shanholz; Peter J Pronovost; Dale M Needham Journal: Intensive Care Med Date: 2017-12-26 Impact factor: 17.440
Authors: Margaret S Herridge; Catherine M Tansey; Andrea Matté; George Tomlinson; Natalia Diaz-Granados; Andrew Cooper; Cameron B Guest; C David Mazer; Sangeeta Mehta; Thomas E Stewart; Paul Kudlow; Deborah Cook; Arthur S Slutsky; Angela M Cheung Journal: N Engl J Med Date: 2011-04-07 Impact factor: 91.245
Authors: Ann M Parker; Thiti Sricharoenchai; Sandeep Raparla; Kyle W Schneck; O Joseph Bienvenu; Dale M Needham Journal: Crit Care Med Date: 2015-05 Impact factor: 7.598
Authors: Lilian Maria Sobreira Tanaka; Luciano Cesar Pontes Azevedo; Marcelo Park; Guilherme Schettino; Antonio Paulo Nassar; Alvaro Réa-Neto; Luana Tannous; Vicente Ces de Souza-Dantas; André Torelly; Thiago Lisboa; Claudio Piras; Frederico Bruzzi Carvalho; Marcelo de Oliveira Maia; Fabio Poianas Giannini; Flavia Ribeiro Machado; Felipe Dal-Pizzol; Alexandre Guilherme Ribeiro de Carvalho; Ronaldo Batista dos Santos; Paulo Fernando Guimarães Morando Marzocchi Tierno; Marcio Soares; Jorge Ibrain Figueira Salluh Journal: Crit Care Date: 2014-07-21 Impact factor: 9.097
Authors: Sebastian Blecha; Magdalena Brandl; Florian Zeman; Frank Dodoo-Schittko; Susanne Brandstetter; Christian Karagiannidis; Thomas Bein; Christian Apfelbacher Journal: Ann Intensive Care Date: 2020-05-06 Impact factor: 6.925